Novartis Contributes Data And Expertise to Cancer Moonshot
Oct 17, 2016
Cancer is a leading cause of death, and cancer incidence is expected to increase worldwide in the coming decades.
There is established, within the Office of the Vice President, a White House Cancer Moonshot Task Force, which will focus on making the most of Federal investments, targeted incentives, private sector efforts from industry and philanthropy, patient engagement initiatives, and other mechanisms to support cancer research and enable progress in treatment and care. The Vice President shall serve as Chair of the Task Force.
In response to the Vice President's call to action and in alignment with the goals of the Cancer Moonshot, representatives from government, academic, pharmaceutical and diagnostic companies have agreed to jump start the development of an open database for liquid biopsies with an initial blood profiling effort.
The Blood Profiling Atlas system, which will include oncology data and expertise from Novartis, will allow approved researchers to access raw unprocessed de-identified datasets in a scalable and reproducible manner. More specifically, Novartis is evaluating the performance of different methods to test circulating tumor DNA ("ctDNA") including PCR-based methods and Next Generation Sequencing-based methods. Novartis will share (i) SOP(s) for plasma collection for ctDNA; (ii) results from evaluation of different commercially available ctDNA extraction kits (iii) evaluation of ctDNA technology performance using contrived samples. In addition, Novartis will share de-identified data and/or de-identified samples generated from these evaluations."